Accueil4559 • TYO
add
Zeria Pharmaceutical Co Ltd
Dernière clôture
2 244,00 ¥
Variation sur la journée
2 247,00 ¥ - 2 274,00 ¥
Plage sur l'année
1 921,00 ¥ - 2 411,00 ¥
Capitalisation boursière
119,94 Md JPY
Volume moyen
63,62 k
Ratio cours/bénéfices
11,86
Rendement (dividendes)
1,99 %
Place boursière principale
TYO
Actualités des marchés
Données financières
Compte de résultat
Chiffre d'affaires
Résultat net
(JPY) | sept. 2024info | Variation Y/Y |
---|---|---|
Chiffre d'affaires | 20,97 Md | 14,11 % |
Charges d'exploitation | 12,52 Md | 14,20 % |
Résultat net | 1,85 Md | -25,47 % |
Marge bénéficiaire nette | 8,82 | -34,67 % |
Bénéfice par action | — | — |
EBITDA | 4,39 Md | 8,29 % |
Taux d'imposition effectif | 17,59 % | — |
Bilan
Total des actifs
Total du passif
(JPY) | sept. 2024info | Variation Y/Y |
---|---|---|
Trésorerie/Invest. court terme | 24,36 Md | 31,90 % |
Total des actifs | 158,34 Md | 6,87 % |
Total du passif | 69,77 Md | -3,36 % |
Total des capitaux propres | 88,57 Md | — |
Actions en circulation | 44,08 M | — |
Ratio cours/valeur comptable | 1,12 | — |
Rentabilité des actifs | 4,06 % | — |
Retour sur capitaux | 4,89 % | — |
Flux de trésorerie
Variation nette en trésorerie
(JPY) | sept. 2024info | Variation Y/Y |
---|---|---|
Résultat net | 1,85 Md | -25,47 % |
Trésorerie (opérations) | — | — |
Trésorerie (invest.) | — | — |
Trésorerie (financement) | — | — |
Variation nette en trésorerie | — | — |
Flux de trésorerie dispo. | — | — |
À propos
Zeria Shinyaku Kōgyō KK is a Japanese drug manufacturer that obtained Tillotts Pharma AG.
In 1955, the Japanese Kisaku Ibu, former Yamanouchi Seiyaku executive opened a new pharmaceutical company in Tokyo under the name Zeria Yakushō Kenkyusho. In 1970, this company becomes Zeria Shinyaku Zeria Shinyaku KK.
In 1975, it built a new factory in Kumagaya in Saitama prefecture, before the main factory in Tsukuba which was constructed by Takenaka Corporation in 1988.
In 2009, the company obtained Switzerland company Tillotts Pharma AG, and began operating internationally through a large network of subsidiaries,
It manufactures and sells pharmaceuticals in Sweden, Ireland, UK, Czech Republic, Spain, Germany, France, Italy, Vietnam and Denmark. The drug itself is developed in Switzerland, Tillotts Parma.
The company owns a 6.63% share of Asuka Seiyaku, also a pharmaceutical company, other than its subsidiaries.
The main shareholder of the company is the company itself, the present president Mitsuhiro Ibu, Mitsubishi UFJ Financial Group, Custody Bank of Japan, Morinaga Milk Industry, SMBC, Mizuho Bank, Risona Bank, Aioi Nissay Dowa Insurance as of March 2023. Wikipedia
CEO
Date de fondation
22 déc. 1955
Site Web
Employés
1 777